Compare Glenmark Pharma with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs VENUS REMEDIES - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA VENUS REMEDIES GLENMARK PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 15.7 -2.9 - View Chart
P/BV x 2.2 0.2 1,119.3% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 GLENMARK PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
VENUS REMEDIES
Mar-18
GLENMARK PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs712126 565.2%   
Low Rs48461 791.5%   
Sales per share (Unadj.) Rs349.6301.8 115.9%  
Earnings per share (Unadj.) Rs32.8-24.9 -131.8%  
Cash flow per share (Unadj.) Rs44.32.5 1,742.2%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs198.6293.3 67.7%  
Shares outstanding (eoy) m282.1712.34 2,286.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.70.3 551.7%   
Avg P/E ratio x18.2-3.8 -484.9%  
P/CF ratio (eoy) x13.536.7 36.7%  
Price / Book Value ratio x3.00.3 943.6%  
Dividend payout %6.10-   
Avg Mkt Cap Rs m168,6251,154 14,614.9%   
No. of employees `00012.00.9 1,301.3%   
Total wages/salary Rs m20,561393 5,230.4%   
Avg. sales/employee Rs Th8,196.04,026.1 203.6%   
Avg. wages/employee Rs Th1,708.1425.0 401.9%   
Avg. net profit/employee Rs Th768.5-331.8 -231.6%   
INCOME DATA
Net Sales Rs m98,6553,724 2,649.1%  
Other income Rs m2,08123 9,250.5%   
Total revenues Rs m100,7363,747 2,688.7%   
Gross profit Rs m15,858395 4,016.8%  
Depreciation Rs m3,259338 963.4%   
Interest Rs m3,346354 944.4%   
Profit before tax Rs m11,335-275 -4,117.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,75632 11,887.3%   
Profit after tax Rs m9,250-307 -3,014.0%  
Gross profit margin %16.110.6 151.6%  
Effective tax rate %33.1-11.5 -288.7%   
Net profit margin %9.4-8.2 -113.8%  
BALANCE SHEET DATA
Current assets Rs m66,9682,638 2,538.9%   
Current liabilities Rs m40,2112,305 1,744.8%   
Net working cap to sales %27.18.9 303.3%  
Current ratio x1.71.1 145.5%  
Inventory Days Days83135 61.5%  
Debtors Days Days8146 175.3%  
Net fixed assets Rs m33,3224,871 684.1%   
Share capital Rs m282123 228.7%   
"Free" reserves Rs m55,7703,496 1,595.4%   
Net worth Rs m56,0523,619 1,548.8%   
Long term debt Rs m35,7381,374 2,600.2%   
Total assets Rs m132,8887,509 1,769.8%  
Interest coverage x4.40.2 1,967.7%   
Debt to equity ratio x0.60.4 167.9%  
Sales to assets ratio x0.70.5 149.7%   
Return on assets %9.50.6 1,501.5%  
Return on equity %16.5-8.5 -194.6%  
Return on capital %17.81.6 1,126.1%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m62,9980-   
Fx outflow Rs m22,859517 4,425.7%   
Net fx Rs m40,140-517 -7,771.5%   
CASH FLOW
From Operations Rs m13,242514 2,574.2%  
From Investments Rs m-6,990-123 5,678.2%  
From Financial Activity Rs m-7,387-387 1,908.4%  
Net Cashflow Rs m-2,9714 -70,733.3%  

Share Holding

Indian Promoters % 48.3 32.9 147.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 0.2 3,833.3%  
FIIs % 34.4 0.6 5,931.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 66.4 15.8%  
Shareholders   56,727 20,121 281.9%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   NATCO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare GLENMARK PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 178 Points Higher; Telecom and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest throughout the day today and ended on a positive note.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jul 3, 2020 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS